GlassScriptPhysician profile
Nina Petroff
NPI 1396836086
$1,171.99
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $31.34 · 2021: $13.80 · 2023: $278 · 2024: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $205.00 | 2019 | |
| Genzyme Corporation | $174.60 | 2023-2024 | |
| Pfizer INC. | $174.55 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $123.36 | 2024 | |
| Incyte Corporation | $101.44 | 2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $92.26 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $87.30 | 2023-2024 | Dupixent, Libtayo |
| Lilly USA, LLC | $85.72 | 2023-2024 | Olumiant |
| Galderma Laboratories, L.P. | $50.94 | 2019 | |
| Prugen, INC. Pharmaceuticals | $29.15 | 2019 | |
| Ucb, INC. | $16.55 | 2024 | Bimzelx |
| Leo Pharma INC. | $15.62 | 2024 | Adbry |
| Aclaris Therapeutics, INC. | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Petroff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.